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Screening interval: a public health blind spot
A preventive strategy of cardiovascular disease is the 
identification and treatment of high-risk individuals.1,2 
One major challenge with this strategy is that it 
requires tools to discriminate high-risk individuals from 
other individuals by appropriate screening tests and 
stratification methods. Furthermore, once individuals 
have been categorised by risk, it might seem that 
everything has been decided: high-risk individuals should 
be treated whereas others should not. However, there 
follows another major issue: should patients initially 
not categorised at high risk be rescreened? And, if yes, in 
which time interval?
In The Lancet Public Health, Joni Lindbohm and 
colleagues help to address this question. Using data on 
6964 individuals followed up for a mean of 22·0 years 
(SD 5·0) with biomedical measurements taken at 5-year 
intervals, the authors estimated the optimal screening 
intervals for cardiovascular disease risk based on 
progression rates from low-risk and intermediate-risk 
categories to the high-risk category.3 They concluded that 
the commonly recommended 5-year screening intervals 
to detect individuals at high risk of major cardiovascular 
events are unnecessarily frequent for low-risk individuals 
and insufficiently frequent for intermediate-risk 
individuals. On the basis of their analyses, they propose 
to tailor screening intervals according to initial risk 
estimates—that is, 7 years for low-risk individuals, 4 years 
for intermediate-low-risk individuals, and 1 year for 
intermediate-high-risk individuals. Their model suggests 
that such a strategy would improve prevention of major 
cardiovascular events without raising health-care costs.
This study suggests that a one-size-fits-all screening 
interval is not optimal and that personalised risk-
based screening intervals could be more efficient for 
the prevention of cardiovascular disease. Conceptually, 
the idea is very simple: patients’ information on 
cardiovascular disease risk gathered at each screening is 
used to tailor the interval until the subsequent screening. 
With this information, prediction of cardiovascular 
disease risk progression is improved, hence allowing 
shortening or lengthening of the time until the next 
screening depending on the expected speed of change in 
risk category.
Surprisingly, very few studies have been designed to 
determine optimal screening intervals for cardiovascular 
disease risk and related risk factors, including blood 
lipid or blood pressure.4 For instance, blood lipids are 
measured at an initial screening visit: if the level is 
satisfactory, no treatment is initiated, but because 
blood lipid tends to increase with age, rescreening 
will eventually be necessary. The question is how 
often should rescreening take place? Annually? Less or 
more frequently? A major challenge is to account for 
random variability inherent to the individual, which 
makes it difficult to identify long-term changes in lipid 
(or risk) level—ie, the signal upon which the decision 
to intervene is based—given the short-term within-
person variation—ie, the noise.5,6 Hence, in the absence 
of treatment, most differences in blood lipid readings 
within a 3-year period have been shown to be due to 
random biological variability or measurement error.7 
Based on this finding, the ideal blood lipid rescreening 
interval among untreated patients could be at least 
3 years, a longer interval than usual practice.4
For hypertension, the standard is routine blood 
pressure screening at every visit, regardless of patient 
complaint, previous measures, or the interval since 
the last measures; this blind, uninformed approach 
is simple but surely not efficient, calling for a more 
informed, data-driven, screening strategy.8 One study 
suggests that the optimal interval could be 3 years or 
more for patients with systolic blood pressure less than 
130 mm Hg and 2 years for those with systolic blood 
pressure of at least 130 mmHg;9 this is a risk-based 
strategy to tailor screening intervals.
In practice, many physicians tend to screen too 
often for cardiovascular disease risk.4,10 Although 
personalising cardiovascular disease risk screening 
intervals, as suggested by Lindbohm and colleagues, 
is very appealing, it is complex because it requires 
adequate tools to estimate cardiovascular disease risk 
at the point of care and an efficient information system 
to record this risk and track its progression over the life 
course. This process seems difficult to implement in 
most clinical settings. The growing use of electronic 
health records, coupled with appropriate algorithm and 
cardiovascular disease risk estimators, will surely open 
new avenues in this field.
Meanwhile, we have to keep in mind that the public 
health issues at stakes are huge as the burden and cost 
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of screening and lifelong monitoring of cardiovascular 
disease or other chronic diseases and related risk factors 
is growing exponentially in ageing populations.
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